BioSpace Movers & Shakers, Dec. 11

Candel Therapeutics – Paul-Peter Tak has been named President and Chief Executive Officer of Candel Therapeutics. Most recently, Tak was President and Chief Executive Officer of Kintai Therapeutics and a Venture Partner at Flagship Pioneering. Previously, he was Senior Vice President and Global Head of Research and Development for Immune Inflammation, Oncology and Infectious Diseases, Chief Immunology Officer and Global Development Leader at GlaxoSmithKline and Co-Chair of the GSK Scientific Review Committee. Tak was previously President and CEO of Tempero Pharmaceuticals, where he facilitated GSK’s acquisition of the company. He co-founded Sitryx Therapeutics and Arthrogen and served on the boards of directors of Sitryx Therapeutics, Levicept and Citryll. Previously, he served on the board of directors of various companies including ViiV Healthcare, Galvani Bioelectronics and Omega Therapeutics. The company has also named Nathan Caffo as Chief Business Officer, John Canepa as Chief Financial Officer and Susan Stewart as Chief Regulatory Officer. Caffo was most recently Chief Business Officer at ALX Oncology. Prior to ALX Oncology, he was President and CEO of Presage Biosciences. He has also worked in business development and management at Perlegen, Applied Biosystems and Celera. Prior to joining Candel, Canepa was the CFO of Frequency Therapeutics. Prior to joining Freilency, he was CFO of Agilis Pharmaceuticals, Inc. Prior to Agilis, he was COO and CFO of Asterand Bioscience. Canepa started his career at Arthur Andersen & Co. and was with the company for 23 years. Stewart was Chief Regulatory Officer at Kaleido Biosciences and Senior Vice President, Regulatory Affairs and Quality. She previously held regulatory and leadership roles at Abbott, Genzyme, Tokai and Transmolecular.

Dotmatic – Dotmatics Ltd. based in the UK, has named Matt Burnett as its new chief technology officer. Burnett was the founder of EIBS, a company developing web and mobile content solutions for the public and third sectors, including the NHS. After the acquisition of EIBS by Ideagen plc in 2014, he became CTO of the Ideagen Group. Burnett joins Dotmatics from Commify, one of Europe’s largest mobile business news companies. He has been CTO since 2017 and supports 45,000 companies in communicating with their customers and employees.

GBT – – Global blood therapeutics announced that Kim Smith-Whitley will join the company as Executive Vice President and Head of Research and Development. Smith-Whitley is the clinical director of hematology and director of the Comprehensive Sickle Cell Center at Philadelphia Children’s Hospital (CHOP). Smith-Whitley will officially join GBT in 2021 and will serve in an advisory capacity in the meantime. After joining the company, she plans to continue to see patients part-time. Smith-Whitley is a former chief medical officer of the Sickle Cell Disease Association of America, where she continues to serve on the board of directors.

Avadel Pharmaceuticals – Jennifer Gudeman has been hired as the first Vice President, Medical and Clinical Affairs for Avadel Ireland. Her duties include overseeing all medical and clinical activities, including the company’s executive program, once a night FT218. Prior to joining Avadel, Gudeman was Vice President of Medical Affairs at AMAG Pharmaceuticals, leading a team of medical science connections and scientific communications. She was previously the director of medical affairs at Lumara Health. She started her industrial career at Mallinckrodt Pharmaceuticals.

Oyster point – Marian Macsai has been named Chief Medical Officer and Eric Carlson has been named Chief Scientific Officer of Oyster Point Pharma. Macsai will oversee medical affairs and clinical development at Oyster Point and Carlson will oversee the discovery, research and development pipeline. Most recently, Macsai held a key leadership position as director of ophthalmology for the health system at NorthShore University and is also a clinical professor of ophthalmology at the University of Chicago’s Pritzker School of Medicine. She was President of the Cornea Society and Chair of the Eye Bank Association of America. Carlson was most recently CSO at Akorn Pharmaceuticals and previously Head of Global Research and Development at Aerie Pharmaceuticals. He was also Head of Ophthalmology at Alcon / Novartis.

Kronos Bio – Pasit Phiasivongsa has been appointed Head of Pharmaceutical Development at Kronos Bio. Most recently, he was Senior Vice President, Technical Operations at Principia Biopharma, a Sanofi company. Prior to Principia, he was Vice President of Pharmaceutical Development at Tobira Therapeutics. Early in his career, he worked in drug discovery, development, and manufacturing at Dynavax Technologies, Onyx Pharmaceuticals, Proteolix, Inc., Astex Pharmaceuticals, and Optimer Pharmaceuticals. He began his career as a research fellow at Cell Pathways, Inc.

Entrada Therapeutics – Nerissa Kreher has been named CMO and Kory Wentworth has been named Chief Financial Officer of Entrada Therapeutics. Kreher joins Entrada after developing a clinical and regulatory strategy as an AVO at AVROBIO and Tiburio Therapeutics. Previously, Kreher was Global Head of Clinical and Medical Affairs at Zafgen and held positions of increasing responsibility at EMD Serono, Genzyme, Enobia / Alexion and Shire Pharmaceuticals. Wentworth joins Entrada after his last position as Head of Finance and Treasurer, Principal Accounting Officer at bluebird bio. Prior to Bluebird Bio, Wentworth was Executive Director and Corporate Controller at Alexion Pharmaceuticals and held positions of increasing responsibility at PricewaterhouseCoopers LLP, KPMG and Arthur Andersen.

SeraNovo – Michiel Van Speybroeck has been appointed Chief Development Officer at SeraNovo in the Netherlands. Most recently, he was Corporate Technology Officer at Ardena, where he was responsible for the technical integration of the company’s services and the management of cross-functional chemical-pharmaceutical development programs to support early-stage clinical trials. He was previously Head of Formulation at the same company. Before joining Ardena, Van Speybroeck was Director of R&D and then CSO at Formac Pharmaceuticals. His primary responsibility was to oversee internal and external research and development programs to evaluate the benefits of the company’s proprietary solubility-enhancing drug delivery technology.

Cannex Scientific – Rebecca O. Bagley has been named Managing Director of Cannex Scientific, where she will lead the development of new cannabinoid-based pharmaceutical solutions. Bagley most recently served as Vice Chancellor for Business Partnerships at the University of Pittsburgh. Previously, she was CEO of NorTech and focused on integrative private public partnerships to accelerate product time to market.

Enanta Pharmaceuticals – Tara L. Kieffer has been named Senior Vice President, Strategy and New Product Development. Kieffer joins Enanta from Vertex Pharmaceuticals, where she has held a role of increasing responsibility. Most recently she was Vice President for External Innovation, Business Development. Previously, she was Vice President of Integrated Program Management, where she led Vertex’s internal development pipeline and product marketing. Previously, she was Senior Director and Chief of Staff of the CMO. Prior to joining Vertex, Kieffer was at Johns Hopkins University Medical School in the Department of Molecular Biology and Genetics.

Cerevance – David Lubner has been appointed to the privately held Cerevance Board of Directors. Lubner was most recently Executive Vice President and Chief Financial Officer of Ra Pharma, which was acquired by UCB in April of this year. Prior to joining Ra Pharma, he was a member of the senior management teams of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc. Lubner currently serves on the board of directors of Dyne Therapeutics and several other private biotechnology companies.

Dew point therapeutics – Kara Carter has been named senior vice president of Discovery Biology. Most recently, she was Executive Vice President, Infectious Diseases at Evotec, where she led Virology Therapy, built a solid program pipeline and led a team in Lyon, France. Prior to Evotec, Carter led the virological therapy portfolio at Sanofi. During her tenure at Sanofi, she held various roles of increasing responsibility, including leading due diligence for business development in infectious diseases, immunology and rare diseases, as well as building and leading functional groups in small molecule drug discovery and leading projects in several therapeutic areas, including neurodegeneration, oncology, immunology, kidney disease, rare diseases, and metabolic diseases.

Novavax – Margaret G. McGlynn has been appointed to the Novavax Maryland Board of Directors. McGlynn is currently the President and Chairman of the Board of Directors of HCU Network America, an advocacy group dedicated to supporting the needs of those affected by the rare genetic disorder homocystinuria (HCU) and related diseases. Prior to founding HCU Network America, McGlynn was President and CEO of the International AIDS Vaccine Initiative. She spent more than two decades at Merck, where she held increasingly responsible roles including President of Merck Vaccines and Infectious Diseases and President of the US Hospital and Specialty Products Division. She currently serves on the boards of Amicus Therapeutics and Vertex Pharmaceuticals.

Synlogic – Michael Heffernan was won over to Synlogic’s Board of Directors. Heffernan is the founder and CEO of Collegium Pharmaceutical, where he served as President and CEO until June 2018. He co-founded Avenge Bio and was previously CEO of Onset Dermatologics. Heffernan previously held positions as Co-Founder and CEO of Clinical Studies Ltd. and later was CEO and Chairman of PhyMatrix Corp.

Molecular assemblies – Phil Paik has been named Vice President of Platform Development at Molecular Assemblies. Prior to joining Molecular Assemblies, he was Associate Director of Engineering at Illumina. Paik began his career as a founding member of Advanced Liquid Logic, which was acquired by Illumina.

Comments are closed.